{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-000543","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.907615+00:00","generated_at":"2026-06-20T09:24:47.623141+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Tonix reports preliminary 2022 cash $120.2M; burn $98.1M; new $12.5M buyback","bullets":["Preliminary cash $120.2M at Dec 31, 2022; shares outstanding 76.5M then, 60.9M as of Jan 24, 2023 after repurchases.","Net cash used in operations $98.1M in FY2022 vs $75.6M in FY2021; capex $48.1M vs $35.3M.","Equity proceeds from stock sales $94.5M in 2022 vs $212.4M in 2021.","Since Jan 1, 2023 repurchased 15.7M shares at $0.44-$1.38 under existing $12.5M program.","Board approved new $12.5M share repurchase program funded with available cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-000543","json":"https://secwatch.observer/filing/0001387131-23-000543.json","markdown":"https://secwatch.observer/filing/0001387131-23-000543.md","text":"https://secwatch.observer/filing/0001387131-23-000543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123000543/0001387131-23-000543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123000543/tnxp_8k-012523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T09:24:47.623141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f69167cf8c36a409821f898c4fea4af86362665e","claim":"Tonix Pharmaceuticals Holding Corp. reported preliminary financial results for the year ended December 31, 2022.","evidence_excerpt":"Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the year ended December 31, 2022, and certain preliminary financial condition information as of December 31, 2022, as set forth below:","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123000543/0001387131-23-000543-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}